Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom

INTRODUCTION: The glucagon-like peptide-1 (GLP-1) receptor agonist class has grown in the last decade, with several agents available in the UK. However there is currently a paucity of evidence regarding the relative cost-effectiveness of liraglutide 1.2 mg versus other daily administered GLP-1 recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Barnaby, Ye, Qing, Valentine, William J., Ashley, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306118/
https://www.ncbi.nlm.nih.gov/pubmed/28058656
http://dx.doi.org/10.1007/s13300-016-0219-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306118/
https://www.ncbi.nlm.nih.gov/pubmed/28058656
http://dx.doi.org/10.1007/s13300-016-0219-2

Ejemplares similares